Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CUG252
- Development stage
- Phase 1
- Lead developer
- Cugene
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
CUG252 is an engineered interleukin-2 (IL-2) mutein designed to selectively activate and expand immune-suppressive regulatory T cells (Tregs), while reducing undesired IL-2 activity on other IL-2 receptor-expressing cells. This selectivity aims to provide immunosuppression for the treatment of autoimmune and inflammatory diseases. The drug is being developed by Cugene, with AbbVie holding an exclusive worldwide license option. It is currently in Phase 1 clinical trials for several autoimmune indications, including systemic lupus erythematosus, atopic dermatitis, inflammatory bowel disease, and rheumatoid arthritis. The modality is a long-acting fusion protein administered subcutaneously[1][3][4][5].
- Other names
- CUG 252CUG252CUG-252
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on CUG252.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CUG252.